JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)

JOHNSON & JOHNSON

2023-FY EPS reported $13.72 revenue$85,159,000,000

Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).
Q4 net earnings from continuing ops $4,132M (diluted EPS $1.70, +39.3% YoY).
Adjusted Q4 net earnings from continuing ops $5,562M (diluted EPS $2.29, +11.7% YoY).
Innovative Medicine ex-COVID vaccine grew 9.7% in Q4; MedTech grew 13.3%.
FY 2023 operational sales growth 7.4% total, 8.0% ex-COVID vaccine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.